NASDAQ:PHAT

Phathom Pharmaceuticals - PHAT News Today

$6.19

-0.09 (-1.43%)

(As of 03/24/2023 12:00 AM ET)

Add

Compare

Today's Range: $5.84
▼
$6.22
50-Day Range: $6.19
▼
$12.36
52-Week Range: $5.84
▼
$16.07

Volume: 380,042 shs
Average Volume: 383,943 shs
Market Capitalization: $259.79 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $20.17

Institutional Ownership

Get Phathom Pharmaceuticals News Delivered to You Automatically

PHAT Media Mentions By Week

PHAT Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

PHAT
News Sentiment
▼
0.30

0.66
▲
Average
Medical
News Sentiment

PHAT News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

PHAT Articles
This Week
▼
3

2
▲
PHAT Articles
Average Week

Source

Source	Headline
	Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Receives $20.17 Consensus PT from Brokerages americanbankingnews.com - March 22 at 1:24 AM
	Analysts Are Bullish on These Healthcare Stocks: Stoke Therapeutics (STOK), Arcutis Biotherapeutics (ARQT) markets.businessinsider.com - March 16 at 8:57 AM
	Craig-Hallum Initiates Coverage of Phathom Pharmaceuticals (PHAT) with Buy Recommendation msn.com - March 14 at 6:46 PM
	All You Need to Know About Phathom Pharmaceuticals, Inc. (PHAT) Rating Upgrade to Buy finance.yahoo.com - March 7 at 3:25 PM
	Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update finance.yahoo.com - February 28 at 8:09 AM
	Needham Reaffirms Their Buy Rating on Ionis Pharmaceuticals (IONS) markets.businessinsider.com - February 23 at 8:05 AM
	Phathom Pharma Shares Fall After Formal FDA Request For Vonoprazan Data finance.yahoo.com - February 18 at 9:51 AM
	ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Phathom Pharmaceuticals, Inc. Investors to Inquire About Securities Class Action Investigation - PHAT benzinga.com - February 14 at 2:12 AM
	Phathom Pharmaceuticals Shares Drop 27% After FDA Response Letters marketwatch.com - February 10 at 1:20 PM
	Where Phathom Pharmaceuticals Stands With Analysts markets.businessinsider.com - February 10 at 1:20 PM
	Phathom’s stock falls after receiving FDA letters finance.yahoo.com - February 10 at 8:19 AM
	Phathom Pharmaceuticals Down 22% on FDA Rejection marketwatch.com - February 9 at 8:20 PM
	TOP RANKED ROSEN LAW FIRM Encourages Phathom Pharmaceuticals, Inc. Investors to Inquire About Securities Class Action Investigation – PHAT benzinga.com - February 9 at 5:06 PM
	Phathom Pharmaceuticals Provides Regulatory Updates finance.yahoo.com - February 9 at 5:06 PM
	Analysts Have Conflicting Sentiments on These Healthcare Companies: Teva Pharmaceutical (TEVA), Atara Biotherapeutics (ATRA) and Galapagos (GLPG) markets.businessinsider.com - February 9 at 10:18 AM
	Bragar Eagel & Squire, P.C. Is Investigating Credit Acceptance, and Phathom and Encourages Investors to Contact the Firm benzinga.com - February 3 at 10:26 PM
	ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Phathom Pharmaceuticals, Inc. Investors to Inquire About Securities Class Action Investigation - PHAT benzinga.com - January 31 at 4:13 PM
	ROSEN, A TOP RANKED LAW FIRM, Encourages Phathom Pharmaceuticals, Inc. Investors to Inquire About Securities Class Action Investigation – PHAT benzinga.com - January 29 at 5:31 PM
	Why Shares of Phathom Pharmaceutical Jumped This Week finance.yahoo.com - January 28 at 3:04 PM
	Great news for Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT): Insiders acquired stock in large numbers last year finance.yahoo.com - January 24 at 10:17 AM
	Analysts Are Bullish on Top Healthcare Stocks: Jazz Pharmaceuticals (JAZZ), Legend Biotech (LEGN) markets.businessinsider.com - January 20 at 11:42 AM
	Phathom Pharma gains on Phase 3 results for heartburn therapy msn.com - January 9 at 1:38 PM
	Phathom Pharmaceuticals Announces Positive Topline Results from Phase 3 PHALCON-NERD-301 Trial Evaluating Daily Dosing of Vonoprazan for Symptomatic Non-Erosive Gastroesophageal Reflux Disease (NERD) finance.yahoo.com - January 8 at 6:24 PM
	The Zacks Analyst Blog Highlights Geron, Chemomab Therapeutics, Phathom Pharmaceuticals, Vera Therapeutics and Novavax finance.yahoo.com - January 6 at 7:38 AM
	Phathom (PHAT) Down on Regulatory Update on Vonoprazan NDA sg.finance.yahoo.com - January 6 at 1:01 AM
	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Phathom Pharmaceuticals, Inc. - PHAT benzinga.com - January 5 at 3:01 PM
	Biotech Stock Roundup: GERN Surges on Study Data, PHAT, VERA Offer Updates & More finance.yahoo.com - January 5 at 3:01 PM
	BMO Capital Maintains Outperform Rating for Phathom Pharmaceuticals: Here's What You Need To Know benzinga.com - January 4 at 1:06 PM
	Phathom Pharma Shares Drop 39% After Delay of Vonoprazen Launch marketwatch.com - January 4 at 12:08 PM
	FDA Issues No Action Notice For Phathom Pharma's Investigational Candidate, Shares Plunge finance.yahoo.com - January 4 at 12:08 PM
	Pre-Market Brief: Stocks Mostly Higher Ahead of FOMC Meeting Minutes theglobeandmail.com - January 4 at 7:07 AM
	Vera Therapeutics, Phathom Pharmaceuticals And Some Other Big Stocks Moving Lower In Today's Pre-Market Session benzinga.com - January 4 at 7:07 AM
	Stocks to Watch: Great Elm Group, Phathom Pharma, Vera Therapeutics and NGL Energy Partners marketwatch.com - January 3 at 7:43 PM
	Phathom Pharmaceuticals Shares Tumble 27% on Delayed Vonoprazan Launch Following FDA Decision marketwatch.com - January 3 at 5:15 PM
	Phathom Pharmaceuticals Provides Update on New Drug Application Review of Vonoprazan for Erosive Esophagitis finance.yahoo.com - January 3 at 5:15 PM
	Phathom Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Updates finance.yahoo.com - November 8 at 6:06 PM
	Phathom Pharmaceuticals to Participate in Upcoming Investor Healthcare Conferences finance.yahoo.com - November 3 at 9:39 AM
	Phathom Pharmaceuticals Completes Patient Enrollment in Phase 3 PHALCON-NERD-301 Daily Dosing Trial of Vonoprazan in Non-Erosive Gastroesophageal Reflux Disease (NERD) finance.yahoo.com - October 24 at 11:58 AM
	Phathom Pharmaceuticals Presents New Data Evaluating First-in-Class Potassium-Competitive Acid Blocker (PCAB) Vonoprazan as Novel On-Demand Treatment in NERD at American College of Gastroenterology (ACG) 2022 Annual Scientific Meeting finance.yahoo.com - October 23 at 3:56 PM
	Phathom Pharmaceuticals to Present Latest Data on Vonoprazan at American College of Gastroenterology (ACG) 2022 Annual Scientific Meeting finance.yahoo.com - October 18 at 8:49 AM
	Evonik Industries AG: Evonik and Phathom Pharmaceuticals partner to produce novel acid-blocker vonoprazan finanznachrichten.de - October 10 at 9:58 AM
	Evonik and Phathom Pharmaceuticals partner to produce novel acid-blocker vonoprazan finance.yahoo.com - October 10 at 9:58 AM
	Phathom Pharmaceuticals Rings the Closing Bell nasdaq.com - September 21 at 10:39 PM
	Phathom Pharmaceuticals to Present at the H.C.... benzinga.com - September 8 at 10:58 PM
	Phathom Pharmaceuticals to Present at the H.C. Wainwright 24th Annual Global Investment Conference finance.yahoo.com - September 7 at 9:48 AM
	As Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) hits US$444m market cap, insiders may be dismayed about not purchasing higher quantities finance.yahoo.com - August 17 at 10:59 AM
	ROSEN, A LEADING LAW FIRM, Encourages Phathom... benzinga.com - August 12 at 9:33 PM
	ROSEN, A GLOBALLY RECOGNIZED FIRM, Encourages Phathom Pharmaceuticals, Inc. Investors to Inquire About Securities Class Action Investigation - PHAT apnews.com - August 11 at 8:58 PM
	ONGOING INVESTIGATION NOTICE: The Schall Law Firm Encourages Investors in Phathom Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm marketwatch.com - August 10 at 10:47 AM
	ROSEN, A LEADING LAW FIRM, Encourages Phathom Pharmaceuticals, Inc. Investors to Inquire About Securities Class Action Investigation – PHAT apnews.com - August 6 at 4:10 PM

Get Phathom Pharmaceuticals News Delivered to You Automatically

This page (NASDAQ:PHAT) was last updated on 3/25/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Phathom Pharmaceuticals - PHAT News Today

PHAT Media Mentions By Week

PHAT Media Sentiment

PHAT News Coverage

About MarketBeat

Popular Tools

Financial Calendars

Terms & Info